Aditya Bardia, MD, MPH, discusses recent advancements in the field of breast cancer.
Aditya Bardia, MD, MPH, attending physician, Massachusetts General Hospital, Harvard Medical School, discusses recent advancements in the field of breast cancer.
Bardia says researchers are discovering new targets for hormone receptor-positive (HR+) breast cancer and are understanding more about endocrine resistance.
The results of the BOLERO-2 trial, which looked at the combination of aromatase inhibitors and mTOR inhibitors, have opened up the field to allow endocrine therapies to be combined with other targeted agents to potentially reverse endocrine resistance, Bardia says. These combinations will change the landscape of HR+ breast cancer.
For HER2+ breast cancer, Bardia thinks there will also be more combination therapies of HER2-directed therapies. Double combinations or even triple combinations would eventually obviate the need for chemotherapy, Bardia says.
Bardia thinks researchers need to do a better job in the field of triple negative breast cancer (TNBC). The problem with TNBC, Bardia says, is that it is difficult to know what to target. Finding a positive target will allow researchers and physicians to improve the outcomes of patients with TNBC.
Clinical Pearls
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Experts Warn of Radiation Overtreatment in Older Women With Early-Stage Breast Cancer
March 20th 2024Studies have found that omitting radiation therapy after breast-conserving surgery and/or omitting axillary surgery in women age 70 years or older does not affect their survival when taking endocrine therapy.
Read More
Analyzing ADC Treatment Sequencing in Advanced Breast Cancer
March 15th 2024In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Read More